Spil Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SPIL, and when can generic versions of SPIL drugs launch?
SPIL has five approved drugs.
There are four US patents protecting SPIL drugs.
There are nine patent family members on SPIL drugs in seven countries and nine supplementary protection certificates in four countries.
Drugs and US Patents for Spil
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Spil | ASPRUZYO SPRINKLE | ranolazine | GRANULES, EXTENDED RELEASE;ORAL | 216018-002 | Feb 28, 2022 | RX | Yes | Yes | 11,510,878 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Spil | NIFEDIPINE | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 210838-001 | Apr 16, 2019 | AB2 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-004 | Jan 26, 2018 | RX | Yes | Yes | 9,700,530 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Spil | AMPHOTERICIN B | amphotericin b | INJECTABLE, LIPOSOMAL;INJECTION | 212514-001 | Dec 14, 2021 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Spil Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 6626492 | ⤷ Try a Trial |
Japan | 2017523164 | ⤷ Try a Trial |
Mexico | 2017000384 | ⤷ Try a Trial |
European Patent Office | 3409273 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Spil Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0984957 | 2012/048 | Ireland | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812 |
1411900 | 2011C/016 | Belgium | ⤷ Try a Trial | PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214 |
0124495 | SPC/GB01/006 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727 |
1411900 | SPC/GB11/015 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.